Abstract: The present invention relates to compounds of the formula 1
and to pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The compounds of formula 1 are useful as antibiotic agents. The invention further relates to pharmaceutical compositions and methods of treating bacterial infection using such compounds, and to methods of making the compounds of formula 1.
Abstract: This invention is directed to the (L)-tartaric acid salt of 2-amino-N-{1-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-[3-oxo-3a-pyridin-2-ylmethyl-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo{4,3-c}pyridin-5-yl]-ethyl]-2-methyl-propionamide which is a growth hormone secretagogue and as such is useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compound. The (L)-tartaric acid salt of the compound of this invention is useful in the treatment and/or prevention of osteoporosis, insulin resistance and other conditions or diseases associated with growth hormone deficiency. The (L)-tartaric acid salt of the compound of the present invention is also useful in treating osteoporosis when used in combination with: a bisphosphonate compound; estrogen, Premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin.
Type:
Grant
Filed:
September 7, 1999
Date of Patent:
June 19, 2001
Assignee:
Pfizer Inc.
Inventors:
Philip Albert Carpino, Paul Andrew Dasilva-Jardine, Bruce Allen Lefker, Jerry Anthony Murry
Abstract: This invention relates to compounds of the formula
wherein A, B, R3, R4, R5 and R7 are as defined herein, and to their use in the treatment of stress-related diseases.
Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
Type:
Grant
Filed:
August 12, 1999
Date of Patent:
June 19, 2001
Assignee:
Pfizer Inc
Inventors:
Kim J. Stutzman-Engwall, Hamish McArthur, Yoshihiro Katoh
Abstract: This invention relates to compounds of the formula
and to pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X1 and X2 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1, methods of treating bacterial and protozoal infections by administering the compounds of formula 1, and methods of preparing certain compounds of formula 1.
Abstract: The invention is directed to the mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one, pharmaceutical compositions containing said ziprasidone mesylate dihydrates, and methods of adminsitering the ziprasidone mesylate dihydrates to treat psychotic diseases.
Type:
Grant
Filed:
August 30, 1999
Date of Patent:
June 12, 2001
Assignee:
Pfizer Inc
Inventors:
Frank R. Busch, Carol A. Rose, Russell J. Shine
Abstract: Oral rinse and dentifrice compositions, comprising a phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof; and a cyclodextrin selected from the group consisting of hydroxypropyl &bgr;-cyclodextrin, hydroxyethyl &bgr;-cyclodextrin, hydroxypropyl &ggr;-cyclodextrin, hydroxyethyl &ggr;-cyclodextrin, &agr;-cyclodextrin, methyl &bgr;-cyclodextrin, and mixtures thereof. These compositions are useful in retarding the development of plaque, treating gingivitis, and in treating the presence of micro-organisms in the oral cavity.
Abstract: A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula
or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
Abstract: Methods of treating congestive heart failure in a mammal, especially a human, by co-administration of (1) amlodipine, a pharmaceutically acceptable salt of amlodipine; (2) an ACE inhibitor; and optionally (3) a diuretic and/or (4) digoxin.
Abstract: The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof. Such compounds and salts are tachykinin antagonists.
Type:
Grant
Filed:
June 1, 1998
Date of Patent:
June 5, 2001
Assignee:
Pfizer Inc.
Inventors:
Alexander Roderick MacKenzie, Allan Patrick Marchington, Donald Stuart Middleton, Sandra Dora Meadows
Abstract: This invention relates to novel aryl substituted azabenzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof.
or a pharmaceutically acceptable salt thereof wherein
n is an integer from 1 to 4
X is CH or N;
R1 is H, (C1-C6)alkyl or (C1-C6) alkoxy;
R2 is H, (C1-C6)alkyl or (C1-C6) alkoxy;
each R3 is independently selected from H, (C1-C6)alkyl (C1-C6) alkyloxy, (C1-C6) alkylthio, halo, nitro, cyano, ethynyl, hydroxy and trifluoromethyl;
R4 is H, (C1-C6)alkyl or (C1-C6) alkoxy;
R5 is H, (C1-C6)alkyl or (C1-C6) alkyloxy, trifluoromethyl; and
W is N or C;
Y is N (R4), N, S or O
Z is R4, NR4H, O, or OH;
Provided that when Y═NR4, W═C, Z═O, there is a single bond between YW and a double bond between WZ; and
when Y=O or S, W═C, Z═O, there is a single bond between YW and a double bond between WZ; and
when Y═N, W═N, there is a double bond between YW and Z does not exist.
Type:
Grant
Filed:
May 25, 2000
Date of Patent:
June 5, 2001
Assignee:
Pfizer Inc.
Inventors:
Steven W. Goldstein, William G. Stirtan, Brian A. Sherer
Abstract: A process is described for preparing a compound of Formula (1.3.0):
comprising: establishing a reaction mixture consisting of
in an aprotic solvent; in the presence of NaOH or KOH; optionally in the presence of a phase transfer catalyst, especially a quaternary ammonium salt or a phosphonium salt; followed by heating said reaction mixture under a nitrogen atmosphere.
Abstract: This invention relates to novel 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives of the formula
wherein R1 is C1-C6 alkyl;
R2 is hydrogen, C1-C6 alkyl, halo C1-C6 alkyl or phenyl;
R3 is hydrogen or halo; and
R4 and R5 are independently hydrogen, C1-C6 alkyl or halo C1-C6 alkyl,
their pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and the use of such compounds to treat CNS, gastrointestinal and other disorders.
Abstract: This invention relates to suspensions for oral administration comprising novel trovafloxacin zwitterionic crystals, and processes for preparing such crystals. This invention further relates to other pharmaceutical compositions comprising these novel crystals, and to methods of using these suspensions, and these novel crystals in such other dosage forms, for treating bacterial infections in mammals.
Type:
Grant
Filed:
May 5, 2000
Date of Patent:
May 29, 2001
Assignee:
Pfizer Inc.
Inventors:
Douglas J. M. Allen, Daniel R. Arenson, S. Sonja Sekulic
Abstract: This invention involves optionally substituted 1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one derivatives, their preparation, compositions containing same and method of treating addictive disorders and neurological or mental disorders related to a decrease in cholinergic function.
Abstract: An oral rinse, dentifrice, or oral gel composition comprising:
a) about 0.01 weight % to about 5 weight % of a citrus flavor, citrus flavor ingredient, or mixtures thereof;
b) about 0.01 weight % to about 5 weight % of a phenolic, said phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof; and
c) an orally acceptable carrier.
The claimed composition is useful in retarding the development of plaque, treating gingivitis, and reducing the viable population of micro-organisms in the oral cavity of a mammal.
Type:
Grant
Filed:
April 23, 1999
Date of Patent:
May 22, 2001
Assignee:
Pfizer Inc.
Inventors:
Patricia A. Delli Santi, Dennis G. A. Nelson
Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula
wherein G, R1 and R2 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system and other disorders.
Abstract: The present invention relates to compounds of the formula 1
and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
Type:
Grant
Filed:
May 21, 1999
Date of Patent:
May 22, 2001
Assignee:
Pfizer Inc.
Inventors:
Eric R. Larson, Mark C. Noe, Thomas G. Gant
Abstract: The present invention relates to certain 6-phenyl-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.